A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Nonproliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs BI 1467335 (Primary)
- Indications Diabetic retinopathy
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 21 Sep 2017 Status changed from not yet recruiting to recruiting.
- 23 Aug 2017 Planned initiation date changed from 18 Aug 2017 to 1 Sep 2017.
- 07 Aug 2017 New trial record